Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

First VolitionRx Study Data Presented at CNAPS

Published: Thursday, November 07, 2013
Last Updated: Thursday, November 07, 2013
Bookmark and Share
Initial study results demonstrate detection rate of 75% for colorectal cancer.

VolitionRx Limited announce the publication of preliminary data from an ongoing independent trial of one of its NuQ® assays. Priv.-Doz. Dr. Stefan Holdenrieder will present a poster at the eighth CNAPS (Circulating Nucleic Acids in Plasma and Serum) congress in Baltimore, MD, USA, showing results from his third party study into the effectiveness of a single NuQ assay for detecting patients with colorectal cancers. 

Dr. Stefan Holdenrieder, who coordinated the trial, is based at the Institute of Clinical Chemistry and Clinical Pharmacology at University Hospital Bonn, Rheinische Friedrich-Wilhelms-Universität Bonn. He is an expert in the field of circulating nucleosomes, and is widely published, having authored over 70 journal papers and several patents. Some example relevant publications may be found in the notes below*.

The results from the 90 patient study demonstrate that Volition’s NuQ-5mc assay was able to detect 75% of patients with colorectal cancer (CRC) at 70% specificity compared to healthy samples. The results were validated in a second set of 113 people.

“These initial results are a promising indicator that blood based methylation levels are a valuable biomarker in the diagnosis of colorectal cancer” Dr Holdenrieder commented. “The sensitivity and specificity achieved in the NuQ-5mc trial is comparable to other single-biomarker cancer diagnostic tests such as the widely adopted PSA for prostate cancer.”

“To get such encouraging results from a single assay gives us a solid platform to build on in our larger trials with multiple markers,” said Dr Jake Micallef, Chief Scientific Officer of VolitionRx. “Our approach is to combine two or more assays, which have shown differentiation independently from our current suite of 21 validated NuQ® biomarkers, with the aim of significantly higher sensitivity and specificity than from single markers alone. This initial data is the first in a series of trials currently underway for colorectal cancer diagnosis. In addition to these exciting results from Bonn, we expect to be able to report on our ongoing trials in Mont Godinne  (Belgium) later in the year and the completion of the first 1000 patients of our pivotal Danish study Q1 2014.”

The poster abstract and a PDF of the poster is available on VolitionRx's website at: http://volitionrx.com/technologies-abstracts-papers-posters.html

The full results and methodology of the study have been submitted for publication.

Volition is carrying out several further clinical trials on the effectiveness of the NuQ assays as a cancer diagnostic tool: 

• 3 ongoing multi-cancer studies at University Hospital in Bonn, Germany; including an 800 patient retrospective study and a 2,000 patient prospective study that involves patients with the 20 most prevalent cancers

• A 250 patient study into colorectal cancer at CHU-UCL Mont Godinne Hospital, Belgium 

• A 4,800 patient retrospective study and a 6,000 patient prospective study into colorectal cancer at Hvidovre Hospital, University of Copenhagen, Denmark. 


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

VolitionRx Invests in Laboratory Automation System
Automation will accelerate analysis of blood samples for expanded colorectal cancer screening trial.
Wednesday, August 13, 2014
VolitionRx Extends Agreement with University Hospital Bonn to Include CE Mark Performance Evaluation
The agreement also doubles the Hospital’s prospective trial of 20 cancers, and adds a range of additional vital background work.
Thursday, April 24, 2014
VolitionRx’s NuQ® Assays Demonstrate 80% Detection Rate in Prostate Cancer
Study data also demonstrates ability to distinguish between prostate and colorectal cancer.
Monday, March 17, 2014
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
10X Genomics Releases Linked-Read Data from NIST Genome Samples
Genome in a Bottle Consortium data submission for webinar presentation and public availability.
Watching a Tumour Grow in Real-Time
Researchers from the University of Freiburg have gained new insight into the phases of breast cancer growth.
Childhood Cancer Cells Drain Immune System’s Batteries
Cancer cells in neuroblastoma contain a molecule that breaks down a key energy source for the body’s immune cells, leaving them too physically drained to fight the disease.
Urine Proteins Point to Early-Stage Pancreatic Cancer
A combination of three proteins found at high levels in urine can accurately detect early-stage pancreatic cancer, researchers at the BCI have shown.
Researcher Discovers Trigger of Deadly Melanoma
New research sheds light on the precise trigger that causes melanoma cancer cells to transform from non-invasive cells to invasive killer agents, pinpointing the precise place in the process where "traveling" cancer turns lethal.
Genetic Tug of War
Researchers have reported on a version of genetic parental control in mice that is more targeted, and subtle than canonical imprinting.
Error Correction Mechanism in Cell Division
Cell biologists have reported an advance in understanding the workings of an error correction mechanism that helps cells detect and correct mistakes in cell division early enough to prevent chromosome mis-segregation and aneuploidy, that is, having too many or too few chromosomes.
How to Become a Follicular T Helper Cell
Uncovering the signals that govern the fate of T helper cells is a big step toward improved vaccine design.
Researchers Resurrect Ancient Viruses
Researchers at Massachusetts Eye and Ear and Schepens Eye Research Institute have reconstructed an ancient virus that is highly effective at delivering gene therapies to the liver, muscle, and retina.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!